A Gen 2 Antisence drug....IPO Nasdaq...
Akcea Therapeutics, a late-stage biotech developing therapies for rare lipid disorders, filed on Monday with the SEC to raise up to $100 million in an initial public offering.
The company is being spun out of publicly-traded Ionis Pharmaceuticals (Nasdaq: IONS).
The Cambridge, MA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol AKCA. Akcea Therapeutics filed confidentially on May 6, 2016. Cowen and Company, Stifel and Wells Fargo are the joint bookrunners on the deal. No pricing terms were disclosed.
Read more: http://www.nasdaq.com/article/rare-...-for-a-100-million-ipo-cm765813#ixzz4cmWbdXq2
A Gen 2 Antisence drug....IPO Nasdaq... Akcea Therapeutics, a...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
